CD91:F:F-Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 27.885

Change

-1.67 (-5.65)%

Market Cap

USD 0.31B

Volume

4.25K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.08 (+0.30%)

USD 139.20B
PRAJ:F Amundi Index Solutions - Amund..

+0.08 (+0.30%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.09%)

USD 115.53B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.09%)

USD 115.53B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 57.94B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 57.94B

ETFs Containing CD91:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.36% 93% A 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.36% 90% A- 73% C
Trailing 12 Months  
Capital Gain 32.56% 89% A- 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.56% 86% B+ 69% C-
Trailing 5 Years  
Capital Gain 48.74% 66% D+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.74% 66% D+ 55% F
Average Annual (5 Year Horizon)  
Capital Gain 1.89% N/A N/A 50% F
Dividend Return 1.89% N/A N/A 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 17.67% N/A N/A 70% C-
Risk Adjusted Return 10.69% N/A N/A 44% F
Market Capitalization 0.31B 49% F 44% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.